Quarterly ResultNov 5, 2026, 11:06 AM
Apyx Medical Q3 Sales Up; Net Loss Narrows
AI Summary
Apyx Medical Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026. The company reported an increase in sales for both the third quarter and the nine-month period compared to the previous year. However, the company continues to incur net losses, although the loss has narrowed year-over-year for both periods. Cash and cash equivalents decreased, and total equity also saw a reduction. The company also noted an increase in stock-based compensation expense.
Key Highlights
- Apyx Medical reported Q3 2026 sales of $14.03 million, an increase from $12.88 million in Q3 2025.
- For the nine months ended September 30, 2026, sales were $40.40 million, up from $33.68 million in the prior year period.
- Net loss for Q3 2026 was $1.81 million, or $0.04 per share, compared to a net loss of $1.98 million, or $0.05 per share, in Q3 2025.
- Nine-month net loss for 2026 was $7.02 million, or $0.16 per share, an improvement from a net loss of $9.87 million, or $0.24 per share, in the same period of 2025.
- The company's cash and cash equivalents decreased to $25.78 million as of September 30, 2026, from $31.74 million as of December 31, 2025.
- Total liabilities decreased to $51.63 million from $52.01 million, while total equity decreased to $10.04 million from $14.83 million.
- Stock-based compensation expense increased to $2.14 million for the nine months ended September 30, 2026, from $1.50 million in the prior year period.
Price Impact
More from APYX